From the Journals

Genetic analysis detects novel gene mutations in hemophilia A


 

FROM HAEMOPHILIA

A wide variety of genetic mutations, including two novel variants, were found in a cohort of Vietnamese patients with hemophilia A, according to a recent report.

Dung Vu Luu, MD, of the Hanoi (Vietnam) Medical University and his colleagues conducted a genetic analysis of 103 patients with hemophilia A. The results of the analysis were reported in a letter to the editor published in Haemophilia.

“In this letter, we report the spectrum of F8 mutations in Vietnamese patients with a well‐established clinical diagnosis of hemophilia A,” the researchers wrote.

Clinical assessment and validation of hemophilia was completed by hematologists from Vietnam’s National Institute of Hematology and Blood Transfusion. The team analyzed DNA that was extracted and isolated from blood samples collected from the patients.

After analysis, the researchers found that disease-causing genetic variants were present in 89% of patients. The intron 22 inversion mutation was detected in 34% of patients in the cohort.

Dr. Luu and his colleagues reported that two novel F8 mutations were also detected that resulted in a severe clinical phenotype: c.4550‐4551insA; p.His1518Serfs*13 and c.1268‐1269insG; p.Asp366GluFs*5.

“To our knowledge, and after an extensive search in many databases, these two variants have not been reported in any F8 mutation database or reported in any published articles,” they explained.

The researchers acknowledged that future studies need to be larger in size.

“The results of this study are adding to the global knowledge base for [hemophilia A] and thus will promote better awareness for molecular diagnosis and care for [hemophilia A] patients in Vietnam,” they wrote.

The study was supported by grant funding from the Ministry of Health of Vietnam. The authors reported having no conflicts of interest.

SOURCE: Luu DV et al. Haemophilia. 2019 Mar 26. doi: 10.1111/hae.13738.

Recommended Reading

Emicizumab may improve thrombosis management in hemophilia A
MDedge Hematology and Oncology
Hemophilia questionnaire proves valid around the globe
MDedge Hematology and Oncology
Prophylaxis maintains high FIX trough levels in hemophilia B
MDedge Hematology and Oncology
PK analysis shows benefit for rFVIII product in hemophilia A
MDedge Hematology and Oncology
Novel assay unable to predict clinical severity in type 1 VWD
MDedge Hematology and Oncology
Ticagrelor reversal agent looks promising
MDedge Hematology and Oncology
SB-525 gene therapy looks viable for hemophilia A
MDedge Hematology and Oncology
Study finds higher than expected rates of hemophilia in Indiana
MDedge Hematology and Oncology
Women with FXI deficiency face hemorrhage risk with gyn surgery
MDedge Hematology and Oncology
Platelet-rich plasma shows promise in hemophilic arthropathy of the knee
MDedge Hematology and Oncology